Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment

Keaton R. Jones, Sarah C. Nabinger, Sangbin Lee, Smiti Snigdha Sahu, Sandra Althouse, Romil Saxena, Mathew S. Johnson, Naga Chalasani, Samer Gawrieh, Janaiah Kota

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives: Hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) exhibit lower tumor microRNA-26a (miR-26a) expression which is associated with worse outcomes. It is unknown if similar miR-26a loss occurs in HCC developed in other liver diseases. We examined tumor miR-26a expression and its impact on recurrence and mortality in a North American HCC cohort. Methods: MiR-26a levels from tumor and surrounding nontumor liver tissue in 186 subjects were collected. We defined lower tumor expression of miR-26a as <1-fold that of the adjacent nontumor liver tissue. Results: Viral hepatitis (42%; 40% hepatitis C and 2% HBV), alcohol (19%), and nonalcoholic fatty liver disease (NAFLD) (18%) were the most common causes of liver disease. The prevalence of lower tumor miR-26a expression was 68%, and it was evident in HCCs arising in all etiologies (viral hepatitis 60%, alcohol 61%, and NAFLD 76%). Subjects with lower tumor miR-26a expression had significantly higher tumor recurrence (hazard ratio [HR], 2.45; 95% confidence interval [CI], 1.18 to 5.1; P = 0.016) and higher mortality of borderline significance (HR, 1.51; 95% CI, 0.94 to 2.41; P = 0.086). Conclusion: Reduced miR-26a expression is a common phenomenon in HCC arising in North American patients with different underlying liver diseases and may increase recurrence and mortality after surgery.

Original languageEnglish (US)
JournalJournal of Surgical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

MicroRNAs
Hepatocellular Carcinoma
Recurrence
Neoplasms
Liver Diseases
Hepatitis B virus
Therapeutics
Hepatitis
Mortality
Alcohols
Confidence Intervals
Liver
Hepatitis C

Keywords

  • biomarker
  • cirrhosis
  • hepatocellular carcinoma
  • liver diseases
  • microRNA-26

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. / Jones, Keaton R.; Nabinger, Sarah C.; Lee, Sangbin; Sahu, Smiti Snigdha; Althouse, Sandra; Saxena, Romil; Johnson, Mathew S.; Chalasani, Naga; Gawrieh, Samer; Kota, Janaiah.

In: Journal of Surgical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{1dd8fbd2cd704c84ac6f6397eb44e84a,
title = "Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment",
abstract = "Background and Objectives: Hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) exhibit lower tumor microRNA-26a (miR-26a) expression which is associated with worse outcomes. It is unknown if similar miR-26a loss occurs in HCC developed in other liver diseases. We examined tumor miR-26a expression and its impact on recurrence and mortality in a North American HCC cohort. Methods: MiR-26a levels from tumor and surrounding nontumor liver tissue in 186 subjects were collected. We defined lower tumor expression of miR-26a as <1-fold that of the adjacent nontumor liver tissue. Results: Viral hepatitis (42{\%}; 40{\%} hepatitis C and 2{\%} HBV), alcohol (19{\%}), and nonalcoholic fatty liver disease (NAFLD) (18{\%}) were the most common causes of liver disease. The prevalence of lower tumor miR-26a expression was 68{\%}, and it was evident in HCCs arising in all etiologies (viral hepatitis 60{\%}, alcohol 61{\%}, and NAFLD 76{\%}). Subjects with lower tumor miR-26a expression had significantly higher tumor recurrence (hazard ratio [HR], 2.45; 95{\%} confidence interval [CI], 1.18 to 5.1; P = 0.016) and higher mortality of borderline significance (HR, 1.51; 95{\%} CI, 0.94 to 2.41; P = 0.086). Conclusion: Reduced miR-26a expression is a common phenomenon in HCC arising in North American patients with different underlying liver diseases and may increase recurrence and mortality after surgery.",
keywords = "biomarker, cirrhosis, hepatocellular carcinoma, liver diseases, microRNA-26",
author = "Jones, {Keaton R.} and Nabinger, {Sarah C.} and Sangbin Lee and Sahu, {Smiti Snigdha} and Sandra Althouse and Romil Saxena and Johnson, {Mathew S.} and Naga Chalasani and Samer Gawrieh and Janaiah Kota",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jso.25156",
language = "English (US)",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment

AU - Jones, Keaton R.

AU - Nabinger, Sarah C.

AU - Lee, Sangbin

AU - Sahu, Smiti Snigdha

AU - Althouse, Sandra

AU - Saxena, Romil

AU - Johnson, Mathew S.

AU - Chalasani, Naga

AU - Gawrieh, Samer

AU - Kota, Janaiah

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Objectives: Hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) exhibit lower tumor microRNA-26a (miR-26a) expression which is associated with worse outcomes. It is unknown if similar miR-26a loss occurs in HCC developed in other liver diseases. We examined tumor miR-26a expression and its impact on recurrence and mortality in a North American HCC cohort. Methods: MiR-26a levels from tumor and surrounding nontumor liver tissue in 186 subjects were collected. We defined lower tumor expression of miR-26a as <1-fold that of the adjacent nontumor liver tissue. Results: Viral hepatitis (42%; 40% hepatitis C and 2% HBV), alcohol (19%), and nonalcoholic fatty liver disease (NAFLD) (18%) were the most common causes of liver disease. The prevalence of lower tumor miR-26a expression was 68%, and it was evident in HCCs arising in all etiologies (viral hepatitis 60%, alcohol 61%, and NAFLD 76%). Subjects with lower tumor miR-26a expression had significantly higher tumor recurrence (hazard ratio [HR], 2.45; 95% confidence interval [CI], 1.18 to 5.1; P = 0.016) and higher mortality of borderline significance (HR, 1.51; 95% CI, 0.94 to 2.41; P = 0.086). Conclusion: Reduced miR-26a expression is a common phenomenon in HCC arising in North American patients with different underlying liver diseases and may increase recurrence and mortality after surgery.

AB - Background and Objectives: Hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) exhibit lower tumor microRNA-26a (miR-26a) expression which is associated with worse outcomes. It is unknown if similar miR-26a loss occurs in HCC developed in other liver diseases. We examined tumor miR-26a expression and its impact on recurrence and mortality in a North American HCC cohort. Methods: MiR-26a levels from tumor and surrounding nontumor liver tissue in 186 subjects were collected. We defined lower tumor expression of miR-26a as <1-fold that of the adjacent nontumor liver tissue. Results: Viral hepatitis (42%; 40% hepatitis C and 2% HBV), alcohol (19%), and nonalcoholic fatty liver disease (NAFLD) (18%) were the most common causes of liver disease. The prevalence of lower tumor miR-26a expression was 68%, and it was evident in HCCs arising in all etiologies (viral hepatitis 60%, alcohol 61%, and NAFLD 76%). Subjects with lower tumor miR-26a expression had significantly higher tumor recurrence (hazard ratio [HR], 2.45; 95% confidence interval [CI], 1.18 to 5.1; P = 0.016) and higher mortality of borderline significance (HR, 1.51; 95% CI, 0.94 to 2.41; P = 0.086). Conclusion: Reduced miR-26a expression is a common phenomenon in HCC arising in North American patients with different underlying liver diseases and may increase recurrence and mortality after surgery.

KW - biomarker

KW - cirrhosis

KW - hepatocellular carcinoma

KW - liver diseases

KW - microRNA-26

UR - http://www.scopus.com/inward/record.url?scp=85052445178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052445178&partnerID=8YFLogxK

U2 - 10.1002/jso.25156

DO - 10.1002/jso.25156

M3 - Article

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

ER -